Clinical Scorecard: Evaluating Atrial Fibrillation Burden and Oral Anticoagulation: A Contextual Approach to Assessing Clinical Benefits Beyond Traditional AF Classifications

At a Glance

Key Highlights

• AF is a major risk factor for ischemic stroke.
• Increasing AF burden correlates with higher risks of ischemic stroke and systemic embolism.
• Low AF burden generally results in low absolute event rates.
• OAC may have limited net clinical benefit in low-burden AF populations due to bleeding risks.
• AF burden should be considered alongside thromboembolic and bleeding risks for anticoagulation decisions.

Guideline-Based Recommendations

Diagnosis

• AF burden should be defined as the proportion of monitored time spent in AF during a defined monitoring period.

Management

• Anticoagulation decisions should consider AF burden, thromboembolic risk, and bleeding risk.

Monitoring & Follow-up

• Continuous longitudinal monitoring is essential for characterizing AF exposure.

Risks

• Increased bleeding risk may offset thromboembolic event reductions in low-burden AF populations.

Patient & Prescribing Data

Patients with varying AF burden, including those with device-detected AF.

The net clinical benefit of OAC is influenced by individual patient factors and AF burden.

Clinical Best Practices

• Utilize continuous rhythm monitoring for better assessment of AF burden.
• Integrate AF burden data into clinical decision-making for anticoagulation therapy.

Related Resources & Content